Here's Why Crispr Therapeutics AG Jumped Again in February

MarketsMotley Fool

What happened

Shares of Crispr Therapeutics AG (NASDAQ: CRSP), a pre-clinical-stage biotech, rose 23.4% in February, according to data from S&P Global Market Intelligence. Offhand comments from the management team at Gilead Sciences, Inc. (NASDAQ: GILD) that imply future deal activity provided the lift.

Continue Reading Below

Crispr Therapeutics is a fledgling biotech that doesn't even have a drug in clinical trials yet, but that's hardly dampening enthusiasm for the company's eponymous gene-editing technology. The shares have risen 113% so far this year.

So what

The latest surge follows comments from Gilead Sciences about its intentions to assemble gene editing capabilities to support a push into oncology.

Gilead didn't mention CRISPR/Cas9 during its fourth-quarter earnings call specifically, but the CEO, John Milligan, made it clear that the company would be investing in various technologies rather than attempt to pick a single winner. Gilead already has access to zinc finger nuclease editing technology through a recent collaboration with Sangamo Therapeutics, and CRISPR/Cas9 seems like a base that needs to be covered.

Now what

Crispr Therapeutics expects to file an application with the FDA later this year that could allow the company to begin human trials before the end of 2018. New drug candidates in pre-clinical development have about a 1% chance of reaching an FDA review. Despite these odds, Crispr Therapeutics' market cap is a shocking $2.05 billion right now.

Gilead completed a $12 billion acquisition recently, but that was for a business that launched a potential blockbuster a couple of months later. If Gilead engages Crispr Therapeutics or any of its peers in the near term, a discovery pact with modest sums up front seems most likely.

10 stocks we like better than CRISPR TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and CRISPR Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 5, 2018

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short May 2018 $85 calls on Gilead Sciences. The Motley Fool has a disclosure policy.